VRTX
US EQUITY
Health Care
Biotechnology
CIK: 875320
Vertex Pharmaceuticals (VRTX) Quant Factor Diagnostic & Fair Value Model
Vertex Pharmaceuticals (Ticker: VRTX) is listed in the Health Care sector (Biotechnology). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$523.93
-2.10%
Latest Close (2026-10-23)
Market Cap: $130.44B
P/E Ratio: 30.4
Momentum Strength
3M / 12M
+9.38%
1M: +0.30%
12M: +22.86%
Quality (ROE)
Point-in-Time
+21.73%
Trailing Return on Equity
Technical Trend
RSI 14
58.7
SMA50: $522.71
SMA200: $477.37
Valuation Multiplier
Trailing
30.4
Premium Multiple (> 30x P/E)
📊
Valuation & Multi-Factor Diagnostic
Premium Multiple (> 30x P/E)
VRTX trades at 30.4x P/E, reflecting market-implied growth expectations for forward revenue and cash flow.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 8/9 (High Financial Strength)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 875320 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-30 | 2026-08-04 | - | $1.10B | $2.55B | $4.31 |
| 10-Q | 2025-12-31 | 2026-08-04 | - | - | - | - |
| 10-Q | 2025-06-30 | 2026-08-04 | - | $1.03B | $1.89B | $3.99 |
| 10-Q | 2026-03-31 | 2026-05-05 | - | $1.03B | $1.43B | $4.02 |
| 10-Q | 2025-03-31 | 2026-05-05 | - | $646.30M | $818.90M | $2.49 |
| 10-K | 2025-12-31 | 2026-02-13 | - | $3.95B | $3.63B | $15.32 |
| 10-K | 2024-12-31 | 2026-02-13 | - | -$535.60M | -$492.60M | $-2.08 |
| 10-K | 2023-12-31 | 2026-02-13 | - | $3.62B | $3.54B | $13.89 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Vertex Pharmaceuticals (VRTX) valuation multiples, momentum factors, and point-in-time filing conventions.
How should VRTX's current valuation multiple be interpreted? ↓
VRTX trades at a trailing P/E of 30.4x within the Health Care sector (premium multiple (> 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are VRTX's key momentum and technical factor indicators? ↓
As of the latest close, VRTX shows a 1-month return of +0.30%, 3-month return of +9.38%, and 12-month return of +22.86%, with a 14-day RSI of 58.7. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for VRTX? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can VRTX be incorporated into systematic factor models? ↓
VRTX can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.